Table 3. Prespecified Secondary End Points by Baseline Community-Acquired Bacterial Pneumonia (CABP) Pathogen in Microbiological Intent-to-Treat Population.
| Baseline CABP Pathogena | Early Clinical Response, No. Successfully Treated/Total No. |
Treatment Difference, % (2-Sided 95% CI) |
Investigator Assessment of Clinical Response, No. Successfully Treated/Total No. |
Treatment Difference, % (2-Sided 95% CI) |
||
|---|---|---|---|---|---|---|
| Lefamulin (n = 205) |
Moxifloxacin (n = 186) |
Lefamulin (n = 205) |
Moxifloxacin (n = 186) |
|||
| Overall response | 186 (90.7) | 173 (93.0) | –2.3 (–8.2 to 3.6) | 176 (85.9) | 163 (87.6) | –1.8 (–8.7 to 5.1) |
| Streptococcus pneumoniae | 110/123 (89.4) | 115/126 (91.3) | 105/123 (85.4) | 108/126 (85.7) | ||
| Penicillin susceptible | 20/26 (76.9) | 36/38 (94.7) | 20/26 (76.9) | 38/38 (100) | ||
| Penicillin resistant | 5/5 (100) | 4/4 (100) | 5/5 (100) | 3/4 (75.0) | ||
| Macrolide resistantb | 7/8 (87.5) | 9/11 (81.8) | 7/8 (87.5) | 10/11 (90.9) | ||
| Multidrug resistantc | 8/8 (100) | 10/12 (83.3) | 8/8 (100) | 11/12 (91.7) | ||
| Staphylococcus aureus | 13/13 (100) | 6/6 (100) | 12/13 (92.3) | 5/6 (83.3) | ||
| Methicillin susceptible | 9/9 (100) | 2/2 (100) | 8/9 (88.9) | 2/2 (100) | ||
| Methicillin resistant | 2/2 (100) | 1/1 (100) | 2/2 (100) | 0/1 | ||
| Haemophilus influenzae | 50/56 (89.3) | 44/48 (91.7) | 52/56 (92.9) | 40/48 (83.3) | ||
| Moraxella catarrhalis | 18/21 (85.7) | 11/11 (100) | 17/21 (81.0) | 11/11 (100) | ||
| Mycoplasma pneumoniae | 20/20 (100) | 14/14 (100) | 19/20 (95.0) | 14/14 (100) | ||
| Legionella pneumophila | 13/16 (81.3) | 16/17 (94.1) | 13/16 (81.3) | 15/17 (88.2) | ||
| Chlamydophila pneumoniae | 15/16 (93.8) | 12/12 (100) | 12/16 (75.0) | 10/12 (83.3) | ||
a
A patient could have had more than 1 pathogen. Multiple isolates of the same species from the same patient were counted once for each phenotype and once for the overall tabulation of the genus and species. Phenotypes were only determined for pathogens identified from cultures and with susceptibility testing results.
b
Resistant to azithromycin or erythromycin.
c
Resistant to 2 or more of the following: oral penicillin, moxifloxacin, ceftriaxone, clindamycin, azithromycin or erythromycin, doxycycline, or trimethoprim/sulfamethoxazole.